- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
Patent holdings for IPC class A61K 31/416
Total number of patents in this class: 2216
10-year publication summary
|
140
|
168
|
163
|
139
|
138
|
141
|
141
|
153
|
151
|
121
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10174 |
39 |
| Glaxo Group Limited | 4336 |
30 |
| Merck Sharp & Dohme LLC | 3734 |
28 |
| The Regents of the University of California | 20868 |
27 |
| F. Hoffmann-La Roche AG | 7796 |
26 |
| Merck Sharp & Dohme Corp. | 2183 |
24 |
| Takeda Pharmaceutical Company Limited | 2698 |
23 |
| AstraZeneca AB | 2817 |
21 |
| Boehringer Ingelheim International GmbH | 4488 |
21 |
| Genentech, Inc. | 4123 |
20 |
| Translatum Medicus Inc. | 30 |
20 |
| Bristol-myers Squibb Company | 4757 |
19 |
| Vanderbilt University | 2030 |
18 |
| Pfizer Inc. | 3414 |
17 |
| Janssen Pharmaceutica N.V. | 3150 |
16 |
| Arena Pharmaceuticals, Inc. | 343 |
16 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 876 |
16 |
| University Health Network | 1068 |
16 |
| Bayer Pharma AG | 1009 |
15 |
| Biosplice Therapeutics, Inc. | 160 |
15 |
| Other owners | 1789 |